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Sodium-Glucose Cotransporter 2 Inhibitors as Preferred Add-on Therapy to Metformin in 
Patients with Type 2 Diabetes Mellitus Who do not Reach Glycemic Goals with Metformin 
Alone 
Abstract 
Diabetes is a national and global health care crisis. Scientists, researchers, and clinicians 
continue to seek the best therapies to optimize diabetes treatment to obtain glycemic goals with 
the least potential for adverse effects, resulting in decreased target end-organ damage, morbidity, 
and mortality. Sodium-glucose cotransporter-2 (SGLT2) inhibitors comprise a novel drug class 
and have shown promise in treating type 2 diabetes. They work by increasing glucose excretion 
through reduced glucose reabsorption in the kidney (Imprialos, Sarafidis, & Karagiannis, 2015), 
independent of pancreatic beta-cell function and insulin resistance, making them effective for use 
at all stages on the diabetes continuum, even in late-stage disease. Numerous studies have shown 
that SGLT2 inhibitors also provide a meaningful reduction in blood pressure; an advantageous 
effect for patients with comorbid hypertension (Heerspink, Perkins, Fitchett, Husain, & Cherney, 
2016). Beta-cell function is estimated to be reduced by 50-60% at the time of diagnosis and 
continues to decline thereafter (Popa & Mota, 2013). An SGLT2 inhibitor, which works 
independently of beta-cell function, is an excellent treatment option if patients fail to achieve 
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Background 
 Diabetes directly affects approximately 12.6% of adults over the age of 20 in the United 
States; is the primary diagnosis associated with over 37 million visits to provider offices, hospital 
outpatient, and emergency departments yearly; and remains the seventh leading cause of death in 
the United States (Centers for Disease Control and Prevention [CDC], National Center for Health 
Statistics, 2017). More than 29 million Americans and 422 million people worldwide are 
estimated to have diabetes (WHO, 2016). Type 2 diabetes accounts for 90-95% of these cases 
(CDC, 2014b).  
 Type 2 diabetes mellitus is a chronic, complex metabolic disorder characterized by 
insulin secretion deficiencies, insulin resistance, or a combination of both, leading to impaired 
glucose homeostasis and hyperglycemia (ADA, 2014). The potential complications of 
inadequately controlled diabetes have been well-documented and include increased risk of 
macrovascular complications, such as coronary artery disease and stroke. Uncontrolled diabetes 
can also lead to increased risk of microvascular complications, such as diabetic retinopathy, 
nephropathy, and neuropathy. Improved glycemic control has been extensively shown to prevent 
the risk or reduce the progression of diabetes-associated microvascular complications (Dunphy, 
Brown, Porter, & Thomas, 2015). Cardiovascular complications, retinopathy, and nephropathy 
associated with diabetes can be further reduced with control of associated hypertension and 
dyslipidemia.      
 Despite the advances made in diabetes research and treatment, the prevalence of the 
disease and, subsequently, its associated morbidity continue to rise (Guariguata, Whiting, 
Hambleton, Beagley, Linnenkamp, & Shaw, 2014). With this rise, researchers and clinicians are 
tasked with finding new, effective, and safe treatment options to minimize the disease burden. 
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 First-line therapy continues to include diet modification, focused on controlling 
carbohydrate intake, and exercise coupled with Metformin drug therapy (American Association 
of Clinical Endocrinologists, 2017; ADA, 2015). Even with the addition of oral antidiabetic 
agents, including glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, 
and glucagon-like peptide-1 analogs used in combination therapy with Metformin, half of 
patients in the United States do not reach goal A1C levels (<7%), and one out of four eventually 
requires insulin therapy (CDC, 2014a). 
 Sodium-glucose cotransporter 2 (SGLT2) inhibitors comprise a new class of medications 
for the treatment of type 2 diabetes. These inhibitors show promise as staples in diabetes 
management. SGLT2 inhibitors increase glucose excretion by the kidneys, work independently 
of pancreatic beta-cells, and are not affected by insulin resistance, making them an attractive 
choice at all stages on the diabetes continuum. As SGLT2 inhibitor use proliferates in diabetes 
therapy, the number of studies evaluating their safety, efficacy, and place in type 2 diabetes 
management continues to increase.  This report seeks to review this available evidence to 
determine if SGLT2 inhibitors should be recommended as preferential second-line add-on 
therapy for the management of type 2 diabetes in patients when Metformin therapy alone is 
insufficient to meet treatment goals. 
   
Literature Review 
Relevance to Case 
 The appendix included as an adjunct to this paper details the case of Dorothea, a patient 
with type 2 diabetes mellitus who is not meeting glycemic goals with her current regimen. 
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Dorothea was diagnosed with type 2 diabetes approximately 10 years ago and has concomitant 
hypertension. Dorothea has been managing her type 2 diabetes with diet and exercise as well as 
Metformin monotherapy dosed at 500 mg twice daily since her diagnosis 10 years ago. 
Unfortunately, when she was recently seen in clinic, her hemoglobin A1C was 8.5%, an increase 
from 8.2 at her last check, and home glucose levels were ranging between 150 and 200 mg/dL. In 
addition to inadequate control of her diabetes, Dorothea’s blood pressure was elevated in clinic 
with a repeat check confirming the elevation. Hypertension treatment was Lisinopril 20 mg once 
daily. An appropriate step-up in Dorothea’s treatment at this time includes increasing her 
Metformin dose (if tolerated without unacceptable GI side effects) and adding 
hydrochlorothiazide for improved control of diabetes and hypertension, respectively. However, a 
consideration for the addition of an SGLT2 inhibitor would be reasonable if adequate control is 
not achieved with the current treatment modifications. Addition of an SGLT2 inhibitor in 
Dorothea’s case could potentially improve control of both diabetes and hypertension. Its 
conceivable use as a preferred second-line add-on therapy to ongoing Metformin use will be 
discussed in this review.  
Literature Search 
 A literature search was conducted via the University of North Dakota’s Harley E. French 
Library website. Databases employed in the search included the Cochrane Library database, the 
Cumulative Index to Nursing & Allied Health Sciences (CINAHL), and PubMed. Search terms 
and mesh terms used were type 2 diabetes mellitus, Metformin, sodium-glucose cotransporter 2 
inhibitors, and add-on therapy. A variety of combinations of the above terms was utilized.  
Results were narrowed to include articles published in 2014 or later and were further narrowed to 
exclude articles focusing on specific SGLT2 inhibitors without generalization to class. 
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Preference was given to meta-analyses and reviews. Selected articles were searched for cross-
references. 
Synthesis of Current Literature 
 Efficacy. 
 Hemoglobin A1C and blood glucose. Reduction of Hemoglobin A1C (HbA1C) (most 
often to less than 7%, but individualized based on comorbidities) is typically identified as the 
primary goal of diabetes management due to its extensive effects on decreasing microvascular 
complications and, to a lesser extent, macrovascular complications (Wildin, Panicker Rajeev, & 
DeFronzo, 2016). Myriad studies have shown that SGLT2 inhibitor use as an add-on to 
Metformin is superior to placebo plus Metformin and at least as effective as glimepiride plus 
Metformin (Brietzke, 2015) and sitagliptin plus Metformin (Sevald, Jackson, & McAna, 2016) in 
regards to lowering HbA1C and fasting glucose levels (Lisenby, Meyer, & Slater, 2016; Whalen 
& St. Onge, 2015; Zhang, Dou, & Lu, 2014). In Zhang et al.’s (2014) meta-analysis on available 
randomized controlled trials, HbA1C lowering effects persisted after one year to a statistically 
significant extent and fasting glucose reductions persisted after two years. Moreover, analyses of 
more recent studies indicated superiority of SGLT2 inhibitor-Metformin combination to DPP-4 
inhibitor–Metformin and sulfonylurea–Metformin combinations in decreasing fasting blood 
glucose and HbA1C (Wilding et al., 2016; Qaseem, Barry, Humphrey, & Fociea, 2017). Wilding 
et al. (2016) further supported the role of SGLT2 inhibitors for glucose reduction, elucidating 
that reductions in glucose are greatest at higher baseline levels because glucose excretion is 
eliminated as a percentage of the total glucose load, signifying that SGLT2 inhibitors are 
effective in those with poorly controlled diabetes.  
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 Body weight. Lifestyle changes, including diet, weight loss, and exercise have been the 
mainstay of diabetes management for years and continue to be considered first-line therapy in 
diabetes treatment, with the addition of Metformin when these are unsuccessful at reaching 
glycemic goals. Obesity increases the risk of developing diabetes, hypertension, hyperlipidemia, 
heart disease, and stroke. Therefore, choosing medications that are weight-neutral or weight-
favorable is ideal. SGLT2 inhibitors have been shown across studies to favorably impact weight, 
presumably via caloric loss through glucosuria (Hasan, Alsahli, & Gerich, 2014). Meta-analyses 
evaluating numerous randomized controlled trials (RCTs) have consistently shown superiority in 
regards to weight loss of SGLT2 inhibitor-Metformin combination versus glipizide-Metformin, 
sulfonylurea-Metformin, and placebo-Metformin combinations (Brietzke, 2015; Maruther et al., 
2016; Qaseem et al., 2017; Wilding et al., 2016; Zhang et al., 2014).  
 Blood pressure, heart rate, and cardiovascular effects. Type 2 diabetes mellitus is a 
well-known risk factor for cardiovascular disease. Adequate control of diabetes and associated 
cardiovascular risk factors, such as hypertension and dyslipidemia, are paramount to decreasing 
the incidence of major adverse cardiac events. A plethora of studies have assessed the effects of 
antidiabetic medications on blood pressure, and more recently, on cardiovascular outcomes, such 
as heart attack and stroke. Across all class members, SGLT2 inhibitors have been shown to 
decrease blood pressure irrespective of underlying hypertension, have done so to a greater extent 
in those with higher baseline pressures, and have had little rebound effect on heart rate 
(Imprialos, 2015; Tikkanen, Chilton, & Johansen, 2016). Numerous additional reviews and meta-
analyses continue to support these findings (Lisenby et al., 2016; Sevald et al., 2016). Head-to-
head comparisons of Metformin-SLGT2 inhibitor combinations versus Metformin-sulfonylurea 
and Metformin-DPP4 inhibitor combinations have indicated preference for Metformin-SGLT2 
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inhibitor combinations in respect to blood pressure and heart rate outcomes and have shown that 
SGLT2 inhibitors as an add-to Metformin were clearly superior to Metformin alone (Maruther et 
al., 2016; Qaseem et al., 2017). 
 Results of a recently completed landmark trial evaluating the impact of the SGLT2 
inhibitor Empagliflozin on cardiovascular outcomes could have a major impact on treatment 
guidelines for patients with diabetes and comorbid heart disease or cardiovascular risk factors. 
As described by Scheen (2016), the EMPA-REG OUTCOME trial (Empagliflozin, 
Cardiovascular Outcomes, and Mortality in Type 2 Diabetes), comprised of over 7000 patients 
with cardiovascular disease and type 2 diabetes, sought to identify the effects of empagliflozin 
versus placebo on the primary composite outcome triple MACE (cardiovascular death, non-fatal 
myocardial infarction, and non-fatal stroke). Researchers reported a 14% reduction in triple 
MACE, as well as more than 30% reductions in cardiovascular mortality, overall mortality, and 
hospitalizations related to heart failure in the cohort treated with empagliflozin (Heerspink et al., 
2016; Scheen, 2016). According to Scheen (2016), these protective effects were observed 
regardless of the patient’s blood pressure at baseline. Additionally, patients in the empagliflozin 
treatment group used anti-hypertensives less frequently than those in the placebo group, which 
could have blunted the overall reported effect of blood pressure lowering of empagliflozin 
(Scheen, 2016). Of interest, stroke risk was not noted to be decreased in the treatment group of 
the EMPA-REG trial; an outcome some theorize could be due to the study population’s relatively 
well-controlled blood pressures at baseline (Scheen, 2016).  
 The other SGLT2 inhibitors approved for use by the FDA in the United States are 
currently undergoing their own detailed trials to evaluate effects on cardiovascular outcomes. 
The Canagliflozin Cardiovascular Assessment Study, due to be completed in June of 2017, is 
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looking at the effect of canagliflozin on CV death, nonfatal myocardial infarction, and nonfatal 
stroke in patients at risk for or with underlying cardiovascular disease and comorbid uncontrolled 
diabetes (Lisenb et al., 2016). The DECLARE-TIMI 58 trial is evaluating the effect of 
dapagliflozin on cardiovascular death, myocardial infarction, and ischemic stroke in those with 
type 2 diabetes and two or more cardiovascular risk factors or known cardiovascular disease 
(Lisenb et al., 2016). It is set to be completed in April of 2019.  
 Renoprotection. Not only has the class of SGLT2 inhibitors been shown to have 
renoprotective effects, these drugs have been proven safe in many placebo-controlled studies for 
use in patients with an estimated glomerular filtration rate (eGFR) as low as 30 mL‧min-1‧1.73m-2 
(Heerspink et al., 2016). They are, however, likely to be ineffective at eGFR levels less than 30 
mL‧min-1‧1.73m-2 due to their mechanism of action and reliability on renal filtration rates to 
excrete urinary glucose (Whalen & St. Onge, 2015). In reviews by Wildin et al. (2016) and 
Heerspink et al. (2016), authors explicated that SGLT2 inhibitors have been shown to decrease 
glomerular hyperfiltration, end-stage renal disease, renal death, and acute kidney injury. 
Heerspink et al. further discussed the effect of SGLT2 inhibitor use in the reduction of uric acid 
levels, an acid that has been associated with hypertension, renal disease, and cardiovascular 
disease (2016). Although the significance of decreased uric acid levels associated with SGLT2 
inhibitor use has not been fully revealed, the EMPA-REG OUTCOME trial did confirm positive 
effects of empagliflozin on the kidney, namely via reductions in new-onset macroalbuminuria, 
creatinine doubling, decreased eGFR to <45 mL‧min-1‧1.73m-2, the need for dialysis, and renal-
related death (Heerspink et al., 2016). A study looking at the impacts of canagliflozin on renal 
events in patients with diabetes and nephropathy is ongoing and will shed more light on the 
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subject (Canagliflozin and renal events in diabetes with established nephropathy clinical 
evaluation trial; NCT02065791). 
 Safety. 
 Hypoglycemia. Hypoglycemia can lead to confusion, shakiness, weakness, diaphoresis, 
loss of consciousness, seizure, and even death (Dunphy et al., 2015). Therefore, the possibility of 
hypoglycemia is a major consideration when weighing options for diabetes treatment. The 
unique mechanism of action of the SGLT2 inhibitors, being that they function independently of 
pancreatic beta cells and insulin, combined with maximal glucose urinary excretion of about 80 
g/day (less than ½ of the filtered glucose load) results in an extremely low hypoglycemia risk 
with their use (Hasan, Alsahli, & Gerich, 2014). Hypoglycemia has been shown to be less 
prevalent in patients treated with an SGLT2 inhibitor as an add-on therapy to Metformin than 
those treated with add-on glimepiride (Brietzke, 2015) or sulfonylureas (Palmer et al., 2016). In 
fact, Palmer et al. recommended SGLT2 inhibitors as preferred add-on treatment to Metformin in 
those whose major adverse effect concern was hypoglycemia (2016).  
 Genitourinary infections. Perhaps one of the most widely discussed and reported side 
effects of the SGLT2 inhibitor class is the increased incidence of genitourinary infections. Early 
studies of SGLT2 inhibitors showed a statistically significant increase in the risk of genital 
infection when compared with placebo, but no statistically significant difference in the incidence 
of urinary tract infections, regardless of patient reports of urinary tract infections (Kawalec, 
Mikrut, & Lopuch, 2013). Subsequent studies, reviews, and meta-analyses have confirmed that 
risk for genital fungal infections is increased with the use of SGLT2 inhibitors alone or in 
combination therapy and that those patients with a history of genital fungal infections had even 
higher risk, but that these infections were generally mild and rarely (<1% of cases) led to 
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discontinuation of the drug (Brunton, 2015; Heerspink, 2016; Maruther et al., 2016; Qaseem et 
al., 2017; Whalen et al., 2015; Wilding et al., 2016). Heerspink et al. (2016) related that results 
of early studies showing an increase in the rates of urinary tract infections in patients taking 
SGLT2 inhibitors were not replicated in subsequent larger studies. 
 Other safety considerations. Additional side effect associations have been postulated 
with the use of SGLT inhibitors, including increased risk of bladder cancer, volume depletion, 
and fracture. According to Whalen et al., early clinical trials with dapagliflozin indicated an 
increase in the number of bladder tumors in the treatment group (2015). However, half of these 
cases were diagnosed within six months of beginning dapagliflozin and nine of the 10 patients 
diagnosed with bladder tumors had baseline hematuria (Whalen et al., 2015), raising the question 
as to whether these tumors were associated with dapagliflozin use. Bone fractures were not 
increased in the EMPA-REG OUTCOME trial (Heerspink et al., 2016). Additionally, Wilding et 
al. (2016) reported that results of an RCT that followed patients on dapagliflozin for 50 weeks 
showed no significant changes in bone formation or resorption markers. Finally, results of a 
review completed by Maruther et al. (2016) showed low or insufficient strength of evidence of 
risk related to fracture. Concern for volume depletion associated with diuresis from SGLT2 
inhibitors has been raised and is of greatest concern in the elderly, those taking concomitant loop 
diuretics, and those with renal impairment (Brunton, 2015; Hasan et al., 2014; Wilding et al., 
2016). Although this risk has been demonstrated in previous studies, as mentioned above, it was 
not duplicated in the EMPA-REG OUTCOME trial (Heerspink, 2016) and evidence of its risk in 
a review by Maruther et al. (2016) was insufficient or of low strength. Although SGLT2 
inhibitors have not been on the market long enough to determine long-term safety, it is 
reassuring that individuals with “functional depletion of sodium-glucose co-transporter 2 may 
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not have long-term deleterious effects, at least in the individuals followed up to date” (Brunton, 
2015, p. 1073). 
Place in treatment  
 SGLT2 inhibitors are becoming front-runners as an add-on to Metformin in the treatment 
of type 2 diabetes. They have an innovative mechanism of action that sets them apart from other 
oral antidiabetic agents and the potential for positive impact on comorbid conditions that may 
propel them to the top of the treatment algorithm for patients who are not adequately controlled 
on first-line Metformin therapy. Their positive influence on cardiovascular outcomes in patients 
with diabetes, as evidenced in the EMPA-REG OUTCOME trial, makes a recommendation for 
their use as a second-line add-on therapy to ongoing Metformin preferable and, in patients with 
underlying cardiovascular disease or risk factors, prudent. In fact, there has already been a trend 
toward preferential use of SGLT2 inhibitors in patients with comorbid cardiovascular disease not 
at glycemic goal (Heerspink, 2016). The European Society of Cardiology has included 
empagliflozin in its treatment guidelines as a therapy option to decrease heart failure 
hospitalization in patients with diabetes (Ponikowski et al., 2016). Results of ongoing trials 
evaluating the impact of SGLT2 inhibition on renal end points could further augment the 
argument that SGLT2 inhibitors should be at the top of therapeutic algorithm.  
 Although SGLT2 inhibitors have the potential to largely impact outcomes in patients with 
type 2 diabetes, their high costs may make them unattainable to some. Additionally, patients with 
severe or recurrent genital mycotic infections and those at high risk for volume depletion are not 
good candidates for use of this class of medications. The choice of an appropriate second-line 
add-on therapy to Metformin should be personalized to the patient.  
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Learning Points 
• SGLT2 inhibitors should be considered for use as preferred add-on therapy to 
Metformin in patients with type 2 diabetes and comorbid cardiovascular disease 
or cardiovascular risk factors not at glycemic goal.  
• SGLT2 inhibitors may be used as an add-on therapy at any stage on the type 2 
diabetes continuum due to their mechanism of action and low potential for 
hypoglycemia. 
• SGLT2 inhibitors should be used cautiously in the elderly, with concomitant loop 
diuretic use, in patients with hypotension, or other predisposing risk factors for 
volume depletion. 
• SGLT2 inhibitors should be used cautiously in patients with recurrent genital 
mycotic infections. 
• Consider discontinuing SGLT2 inhibitors when eGFR is <30 mL‧min-1‧1.73m-2 as 
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CC: Diabetes Recheck – saw diabetes educator last week and encouraged to come in for follow-
up. 
HPI: Dorothea is a pleasant 60 year-old Caucasian female who presents to the clinic today for 
follow-up of type 2 diabetes. She was diagnosed with diabetes approximately 10 years ago and 
has been well-controlled with Metformin 500 mg twice daily since diagnosis. At her appointment 
with the diabetic educator 3/3/2017, Dorothea revealed that her blood sugars have been elevated 
for the past few months, which prompted the dietician to encourage her to follow-up in clinic 
today.  
 Unfortunately, Dorothea did not bring a record of her blood glucose levels with her to 
this appointment; however, she reports her sugars have been consistently in the 150s to 200 
range. She associates this with a less-than-optimal diet containing increased sweets and fried 
foods. Associated symptoms include increased fatigue for the past few months. She denies 
episodes of hypoglycemia. She has not experienced vision changes, including diplopia or blurred 
vision, headaches, lightheadedness, dizziness, syncope or near syncope, diaphoresis, numbness, 
tingling, sensation loss, polyphagia, polydipsia, polyuria, dysuria. 
 Dorothea also has a history of hypertension, for which she takes Lisinopril 20 mg daily. 
Her blood pressure is elevated in clinic today at 148/98. She does not check blood pressures at 
home or elsewhere outside of the clinic.  
Medications 
Metformin 500 mg twice daily 
Aspirin 81 mg daily 
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Lisinopril 20 mg daily 
Atorvastatin 20 mg daily 
Multivitamin daily 
Allergies 
Penicillin – reaction unknown 
No known latex, medication, or environmental allergies 
PMH/Problem List 




Type 2 diabetes – mother and father 
Social History 
Married with grown children. 
Works at the Simulation center at UND. 
Non-smoker; no history of tobacco use. 
ROS 
General: Denies fever, chills, unintentional weight gain or weight loss, weakness. Positive for 
fatigue. 
HEENT: Regular optometry visits. Wears corrective lenses. Denies eye pain, redness, diplopia, 
blurred vision, floaters, flashers.  
Cardiovascular: No chest pain, palpitations, lower extremity edema 
Respiratory: No cough, shortness of breath, wheeze 
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GI: No nausea, vomiting, diarrhea, constipation 
GU: No dysuria, frequency, urgency 
Endocrine: No numbness, tingling, polyuria, polydipsia, polyphagia 
Physical Exam 
BP  148/98   Pulse  80  Temp  98.6 F  Resp  20   Wt 160 lb stated  Ht  5’8” stated  SpO2  not 
obtained 
Constitutional: Patient is well-groomed, in no acute distress, does not appear ill. 
HENT: Head normocephalic, atraumatic, TMs pearly gray and translucent bilaterally, external 
ears normal, oropharynx clear and moist, posterior pharynx without edema or exudate, soft palate 
rises to phonation 
Eyes: PERRLA, conjunctivae without injection, no discharge, funduscopic exam reveals clear 
disc margins, no evidence of AV nicking, retinopathy 
Neck: supple, no masses, trachea midline 
Cardiovascular: Regular rhythm, S1 and S2 normal. Exam reveals no S3 or S4. No murmur, 
rubs, or gallop. Brisk capillary refill. No peripheral edema. 
Pulmonary/Chest: Effort normal, symmetric unlabored respirations, no respiratory distress, no 
crackles or wheeze, no chest tenderness 
GI: soft, non-tender to palpation, bowel sounds present x4, no splenomegaly 
Lymphadenopathy: No retropharyngeal, submental, submandibular, preauricular, post auricular, 
cervical, occipital, or supraclavicular lymphadenopathy appreciated. 
Neurological: Alert and oriented x 3, normal DTRs. Monofilament exam identifies no sensation 
abnormalities to feet bilaterally 
Skin: Warm and dry, no abnormal lesions or rashes 
SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS  22 
 
Psychiatric: Normal mood and affect. 
Lab data/Diagnostics 
A1C 8.5 (up from 8.2 at last check) 
UA within defined limits 
CMP within defined limits 
Repeat BP in clinic remained elevated 
Assessment 
Uncontrolled Diabetes Mellitus Type 2 
Uncontrolled Hypertension 
Plan 
Dietary changes as discussed in patient’s visit with the diabetic educator 
Increase Metformin to 1000 mg twice daily 
Start hydrochlorothiazide 12.5 mg daily  
Continue at-home blood glucose monitoring (would ideally like some fasting, 2 hours post-meal 
and evening blood sugars) and contact the clinic with any episodes of hypoglycemia (BS <70) 
Monitor blood pressures at home. Contact the clinic with increased dizziness, syncope or near-
syncope, or low blood pressures (SBP/top number <90 or DBP/bottom number <60). 
Follow-up in 2-4 weeks ; sooner with concerns 
Plan to recheck Hgb A1C in 3 months 
Goal A1C <7.0% (if able to achieve without hypoglycemic episodes) 
If A1C level has not improved at 3 month recheck, will consider the addition of an SGLT2 
inhibitor. 
 
